Updates to Statute 1557 that Healthcare Providers Need to Know
Privacy and Healthcare Business Associates with Isabella Porter
State Law Privacy Video Series | Healthcare Entities and Health Data
Gerry Blass on Healthcare Vendor Risk Management
AGG Talks: Technology - In the Balance: Interoperability and Security
Is Your Practice's Marketing HIPAA Compliant?
Relaxed HIPAA Restrictions For Providers Using Telehealth
Compliance Perspectives: Permissible Disclosures under HIPAA, Especially in the Time of COVID-19
Polsinelli Podcasts - Confusion to Clarity on the Future of the 340B Program
Polsinelli Podcast - HIPAA Changes Overview
On July 31, 2025, the U.S. Department of Health and Human Services (HHS) announced that it will conduct a pilot program testing out a rebate model for 340B drug purchases. Under the program, drug manufacturers will be allowed...more
On the heels of multiple lawsuits disrupting drug manufacturers’ efforts to convert the 340B Program into a rebate-based model, the Health Resources and Services Administration (HRSA) released a Notice[1] announcing the...more
Few aspects of the healthcare regulatory apparatus evoke more confusion and dread for healthcare practitioners than the National Practitioner Data Bank (NPDB or Data Bank). Being reported to the Data Bank is often regarded...more
On Thursday, June 13, the next installment of Rivkin Radler’s Healthcare Compliance Lunch & Learn series, will be presented by Rivkin Radler Partner Ashley Algazi and moderated by Robert Hussar. The program, “Conducting HIPAA...more
A periodic feature by Cornerstone Research, in which our affiliated experts, senior advisors, and professionals, talk about their research and findings. We interview Professor Sayeh Nikpay of the School of Public Health,...more
The Federal Corporate Transparency Act (the CTA), 31 U.S.C. §5336, will soon require certain entities to disclose to the U.S. Treasury's Financial Crimes Enforcement Network (FinCEN) certain pieces of identifying information...more
The 340B Drug Pricing Program (the “Program”) allows certain healthcare providers (“covered entities”) to purchase pharmaceuticals from drug manufacturers at discounted rates. Some covered entities do not have an internal...more
Please join us as Rivkin Radler Associate Ashley Algazi presents the September Lunch and Learn. The program will: - Review HIPAA breach definition - Discuss the analysis and investigation process to determine if a...more
Is your physician group monitoring the Open Payments database? Each June, the Centers for Medicare and Medicaid Services (CMS) releases data showcasing the payments made by reporting entities to physician groups and other...more
In this episode, Richard Church, Andrew Ruskin, and Victoria Hamscho discuss recent developments in the 340B Drug Pricing Program, including recent actions by drug manufacturers to limit contract pharmacy access to 340B...more
Every year, we remind our readers that the HIPAA data breach notification regulations require covered entities to notify the Office for Civil Rights (OCR) of any reportable data breaches that involved fewer than 500...more
One health system recently learned the cost of relying too heavily on the HIPAA Breach Notification Rule’s “low probability of compromise” standard when it failed to notify all affected individuals and report the HIPAA breach...more
Pursuant to HIPAA/HITECH, covered entities are required to report breaches of unsecured protected health information that occurred in 2015 and affected less than 500 individuals to the Office for Civil Rights no later than 60...more